Article Text

Download PDFPDF
Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications

Statistics from


  • Handling editor Josef S Smolen

  • Contributors SB, CM-R, RS and XM designed the study. All authors acquired the data. SB, CM-R, RS, XM, PAJ, CV and PD analysed the data. All authors gave final approval to the paper.

  • Funding This study was funded by Pfizer (10.13039/100004319) and grant number: Passerelle.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval This study was approved by the local institutional review board named CPP Île de France VII under number PP 12-030.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Presented at This work has already been presented at the European League Against Rheumatism and published as a conference abstract [10].

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.